Tina Vo
Family · Gardner, MANPI 1083365951
Payments from drug & device makers
Across 35 payments — averaging $88.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$339
- GSK$336
- AbbVie$250
- Takeda Pharmaceuticals U.S.A., Inc.$189
- Novo Nordisk$155
- Cequr Corporation$150
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,100100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $339 |
| GSK | 3 | $336 |
| AbbVie | 3 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $189 |
| Novo Nordisk | 2 | $155 |
| Cequr Corporation | 1 | $150 |
| Heartflow, Inc. | 1 | $148 |
| Dexcom, Inc. | 1 | $136 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi | 1 | $123 |
| Sage Therapeutics, LLC | 1 | $120 |
| Amgen | 1 | $99 |
| Johnson & Johnson | 2 | $95 |
| Xeris Pharmaceuticals, Inc. | 1 | $95 |
| Gilead | 1 | $94 |
| Ultragenyx Pharmaceutical Inc. | 1 | $88 |
| Astellas Pharma US Inc | 1 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $82 |
| Viiv Healthcare Company | 1 | $76 |
| Calliditas Therapeutics US Inc. | 1 | $71 |
| Madrigal Pharmaceuticals | 1 | $68 |
| Kyowa Kirin, Inc. | 1 | $61 |
| Biomarin Pharmaceutical Inc. | 1 | $56 |
| Mylan Specialty L.p. | 1 | $42 |
| Dysis Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$256
- CeQur Simplicity$150
- FFRct$148
- DEXCOM G7 GSS (161)$136
- DEXCOM STELO GLUCOSE BIOSENSOR$136
- VOQUEZNA$125
- DUPIXENT$123
How this compares
$3,100 in reported general payments places this provider in the 90th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 100 | $110,312 |
| OzempicSemaglutide | 61 | $97,464 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $43,278 |
| JardianceEmpagliflozin | 21 | $37,334 |
| EliquisApixaban | 31 | $36,006 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $13,043 |
| MyrbetriqMirabegron | 14 | $9,298 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,586 |
| ConcertaMethylphenidate Hcl | 11 | $7,931 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $7,076 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $6,444 |
| Rosuvastatin Calcium | 186 | $5,653 |
| Atorvastatin Calcium | 307 | $4,816 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,151 |
| Advair DiskusFluticasone Propion/Salmeterol | 25 | $3,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $155 | $97,46461 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $336 | $60,47294 claims |
| Astellas Pharma US IncMyrbetriq | $86 | $9,29814 claims |
| AstraZenecaSymbicort | $339 | $8,58626 claims |
| Johnson & JohnsonConcerta | $95 | $7,93111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,320 family providers in Massachusetts.
Other family in Gardner
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.